Sovilnesib

Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC 50 value of 0.071 μM. Sovilnesib can be used for the research of cancer In Vitro Sovilnesib (AMG 650; 0-10 pM; 96 and 144 h; cancer cell lines) has anti-proliferative activity and inhibits tumor cell growth in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Cancer cell lines Concentration: 0-10 pM Incubation Time: 96 and 144 hours Result: Inhibited tumor cell growth in a dose-dependent manner. In Vivo Sovilnesib (AMG 650; 10-100 mg/kg; p.o. daily, for 45 d; female nude mice without thymus with OVCAR-3 xenografts) inhibits tumor growth, Lasting tumor regression and cure occurred in 50% of the animals, Sovilnesib has no apparent toxicity . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female nude mice without thymus with OVCAR-3 xenografts Dosage: 10, 30, and 100 mg/kg Administration: Oral administration; daily, for 45 days Result: Had antitumor efficacy in a dose-dependent manner. Form:Solid IC50& Target:KIF18A

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet